1. Scrip
  2. >>Business
  3. >>Deals

Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization

 
• By Jessica Merrill

The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.

paper rip
Eisai and Bristol ended an ADC collaboration • Source: Shutterstock

Eisai Co., Ltd.’s partnership with Bristol Myers Squibb Company on the antibody-drug conjugate farletuzumab ecteribulin (FZEC) appears to be a casualty of Bristol’s R&D prioritization program. Eisai announced the end of the three-year partnership on FZEC, formerly known as MORAb-202, on 1 July and said it plans to accelerate development of the product and conduct development and commercialization independently.

Key Takeaways
  • Eisai plans to accelerate development of farletuzumab ecteribulin after regaining full rights from Bristol Myers Squibb.
  • Farletuzumab ecteribulin is a folate receptor alpha (FRα)-targeting ADC in...

Bristol paid handsomely for rights to co-develop and co-commercialize FZEC in regions including the US, Europe and Asia in 2021. (Also see "BMS, Eisai Team Up To Accelerate...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

More from Business

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now